P&T Ulcerative

Syndicated P&T Session: Ulcerative Colitis

MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

MMIT’s syndicated P&T Perspectives session provides qualitative and tangible feedback through a simulated P&T session that informs your brand’s strategy and enables you to understand how your product and/or competitor’s product will fare in an actual P&T Committee review.

Learn how you can use P&T Perspectives to:

  • See how a simulated large, national multi-state health plan will review new to market entrants through a 90-minute live-streaming session with 15-minute Q&A
  • Understand how health plans are running cost analyses on your brand or competitors
  • Learn from autonomously developed session material and clinical dossiers to inform brand strategy and messaging

Interested in obtaining the full video and learning more about how you can take advantage of P&T Perspectives?

Witness the Actual Discussions: